Magnetic resonance imaging is a powerful, noninvasive imaging technique with exquisite sensitivity to soft tissue composition. Magnetic resonance imaging is primary tool for brain tumor diagnosis, evaluation of drug response assessment, and clinical monitoring of the patient during the course of their disease. The flexibility of magnetic resonance imaging pulse sequence design allows for a variety of image contrasts to be acquired, including information about magnetic resonance–specific tissue characteristics, molecular dynamics, microstructural organization, vascular composition, and biochemical status. The current review highlights recent advancements and novel approaches in MR characterization of brain tumors.
From the *UCLA Brain Tumor Imaging Laboratory and Center for Computer Vision and Imaging Biomarkers; Departments of †Radiological Sciences and ‡Biomedical Physics, David Geffen School of Medicine at UCLA; §Department of Bioengineering, Henri Samueli School of Engineering and Applied Sciences at UCLA; and ∥UCLA Neuro-Oncology Program, David Geffen School of Medicine, UCLA, Los Angeles, CA.
Correspondence to Benjamin M. Ellingson, PhD, Departments of Biomedical Physics, Bioengineering, and Radiological Sciences, David Geffen School of Medicine, University of California–Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024 (e-mail: BEllingson@mednet.ucla.edu).
Research support was received from NIH/NCI R21CA167354 (BME), UCLA Jonsson Comprehensive Cancer Center Seed Grant (to B.M.E.), University of California Cancer Research Coordinating Committee Grant (to B.M.E.), Siemens Healthcare Research Grant (to B.M.E.), Art of the Brain (to T.F.C.), Ziering Family Foundation in memory of Sigi Ziering (to T.F.C.), Singleton Family Foundation (to T.F.C.), and Clarance Klein Fund for Neuro-Oncology (to T.F.C.).
The authors declare no conflict of interest.